Watson Biological Adenovirus Vector The new industrialization base for Crown vaccine was established in Daxing

Original title: Watson Biological Adenovirus Vector New Crown Vaccine Industrialization Base based in Daxing

December 27Watson BioNew corona vaccine base set up in Beijing Daxing BiomedicineindustryYuan, this is also China’s first chimpanzee adenovirus vector vaccineIndustrializationbase.Depending onWatson BioAdvantages of industrialization of innovative vaccines and mature productionqualityadministrationSystem, by Zhang Linqi of Tsinghua UniversityprofessorteamWith the team of Professor Zhou Dongming from Tianjin Medical UniversityCooperative research and developmentThe new corona adenovirus vaccine has entered the preparation stage for industrialization and, once it is successfully developed, it will be mass produced at the Daxing base.

　　The new corona vaccine for the adenovirus vector enters the testing phase

At the beginning of the new corona outbreak in early January this year, Professor Zhang Linqi’s team and Professor Zhou Dongming’s team began to cooperate in researching the new corona virus vaccine. May have autonomyKnow howpropertyThe chimpanzee adenovirus vector vaccine has entered the animal safety and efficacy testing phase.

The new corona adenovirus vector vaccine belongs to one of the five technical routes for research and development of vaccines deployed by the country. Professor Zhang Linqi, from Tsinghua University School of Medicine and Vanke School of Public Health and Health, introduced that the five technical routes of China’s new crown vaccine were basically launched in a period of time . The longer the vaccine development cycle, the safer and more effective it will be in humans. .

Preliminary research results show that the vaccine can induce high levels of neutralizing antibodies and specific T-cell immune responses in animals, and has good immunological persistence. Challenge experiments show that the new coronavirus vaccine can protect rhesus monkeys from the new coronavirus attack.

“By knowing how the new coronavirus opens the ‘door’ to the human body, you can learn more about how to protect this ‘door’.” Professor Zhang Linqi pointed out that the S protein from the new coronavirus must combine with the human ACE2 protein before the virus can invade the human body. He compared the protein S of the new coronavirus with a “key” and the ACE2 of the human body with a “lock.” The entry of the new coronavirus into the human body consists of using the “key” to open the “lock” of the ACE2 of the human body, and then enter the cell and begin to replicate in large quantities, causing damage to the human body.

Professor Zhang Linqi’s team took the “key” from protein S and into the modified chimpanzee adenovirus vector. When the carrier transports protein S to human cells, the human immune system will rapidly assemble a specific target for this protein S. Special “key” weapon of death: new antibody against coronavirus. When the real new coronavirus arrives, the special weapons of the human body will already be ready to eliminate the virus outside of human cells and achieve immune protection against the new coronavirus.

　　Almost no side effects, more accurate immune response

Professor Zhang Linqi said that because of the key to catch the only receptor for the new coronavirus to enter the human body, the characteristic of this type of vaccine is that the cells can produce a precise immune response and are more targeted. The adenovirus vector used is derived from a rare chimpanzee serotype. The main reason is that there are generally no pre-stored neutralizing antibodies against chimpanzee adenovirus in the human body. The greatest advantage of using this virus as a carrier vaccine is that the adverse reactions after vaccination are small. There are many advantages in the immunization dose. In terms of safety, immunogenicity, mass production,transportThere are many advantages in terms of storage and storage.

“At present, our vaccines have had no side effects in animals.” Professor Zhang Linqi introduced that he is expected to apply for domestic and foreign clinical trials in late December.productOnce approved, it will be China’s first chimpanzee adenovirus vector vaccine. Compared to human adenovirus vectors, chimpanzee adenovirus vectors have the advantage of less pre-existing immunity in the population.

In addition, because the adenovirus vector vaccine can stimulate the body to produce humoral immunity and cellular immunity, and has better persistence of immunity, productioncostThe low-level characteristics have shown great advantages in the development of the new coronavirus vaccine. So far, polyadenovirus vaccines have entered the clinical stage around the world, and AstraZeneca’s new corona vaccine uses chimpanzee adenovirus vectors.

Professor Zhang Linqi said that since the new coronaviruslongpopularLooking at the trend, the first research and development results of new corona vaccines have appeared, showing good safety and efficacy. But you need to continue to respect long-term protection. As a second follower, they will focus more on the comprehensive capabilities of vaccines, including efficacy, safety, shelf life, scale, and accessibility. “If the production workshop starts now, the vaccine can be reversed on a large scale by the middle of next year.marketuse. Professor Zhang Linqi said.

(Article source:shellFinance)

(Responsible editor: DF062)